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Abstract 
Stents cannulating the common bile duct
and/or the pancreatic duct are frequently used
during endoscopic retrograde cholangiopancre-
atography in both temporary and definitive
management of several conditions. While plas-
tic stents have a high risk of occlusion within a
few months, metal stents have larger diameters
and may, therefore, last longer. However, they
tend to have a higher initial cost and once
placed, tend to be more difficult to manipulate
or remove. Emerging data are now showing that
the removal of covered self-expandable metal
stents can be achieved relatively easily without
the risks of major complications. This review
article investigates the indications and compli-
cations for stent insertion, as well as the recom-
mended type of stent for each indication.
Introduction
Endoscopic retrograde cholangiopancre-
atography (ERCP) is a valuable tool in the
management of hepatobiliary diseases. Stents
cannulating the common bile duct (CBD)
and/or the pancreatic duct (PD) are frequently
used during ERCP in the temporary and defin-
itive management of several conditions. In this
review article, we review the indications, risks
and novel uses of stents during ERCPs.
The stents used during ERCP can be either
plastic or metal. While plastic stents have a
high risk of occlusion within a few months,
metal stents have larger diameters and may,
therefore, last longer. However, they tend to
have a higher initial cost and once placed, tend
to be more difficult to manipulate or remove.1
Emerging data are now showing that the
removal of covered self-expandable metal
stents (CSEMS) can be achieved relatively eas-
ily without the risks of major complications. In
an analysis on the safety and outcome of
removal of fully covered SEMS during ERCP,
Kasher et al. showed that all 37 stent removal
attempts were successfully achieved without
difficulty.2 Indwelling stent-related complica-
tions occurred in 4 of 37 patients, including
secondary strictures in 3 and a minor biliary
leak in one. Two of 3 secondary strictures
occurred at the distal stent margin of oversized
intraductal stents, and another stricture
occurred at a proximal stent margin of an over-
sized transpapillary stent. All of these cases
were treated successfully with repeat stenting
and resolved without further sequelae.
The main indications for the insertion of
stents during ERCP are shown in Table 1.Materials
A Pubmed search was made using the terms
ERCP stents AND cholangiocarcinoma AND
pancreatic carcinoma AND ampullary carcino-
ma AND common bile duct obstruction. Over
38,000 Pubmed results were obtained and
these were reviewed specifically for any refer-
ence to common bile duct stents or pancreatic
duct stents inserted during ERCP. In particular,
the search results were narrowed down to 323
articles dealing with endoscopic treatment and
ERCP stenting of the biliary obstruction. These
articles were further narrowed down to those
dealing with the current recommendations
and novel research on ERCP stents.Cholangiocarcinoma
ERCP is a useful tool in the diagnosis and
management of cholangiocarcinomas.3 On
cholangiography, the appearance of a stricture
can suggest malignancy, although this is
inconclusive. Tissue for cytology during ERCP
can be obtained by brushing, biopsy and bile
aspiration, although in most cases brush cytol-
ogy tends to have a low sensitivity (18-60%).4
Cholangiocarcinoma has a dismal prognosis
with an average 5-year survival of 5-10%.5 The
only curative therapy is surgical resection.
Patients undergoing surgical resection have a
median survival of 37.2-42.9 months while
those not fit for surgical resection have a
median survival of 6.7-11.6 months.6 Surgery
offers a cure for the minority of patients with
cholangiocarcinoma, with a 9-18% 5-year sur-
vival for proximal bile duct lesions and 20-30%
5-year survival for distal lesions.7 Only 10-20%
of patients with cholangiocarcinomas are can-
didates for surgery.
In patients with unresectable disease, bil-
iary decompression for palliative purposes can
be accomplished surgically, radiologically or
endoscopically with endoscopic decompression
being the preferred option. Only 25% of the
liver needs to be adequately drained to relieve
jaundice and provide palliation. Therefore, in
strictures affecting both left and right hila,
unilateral stenting of only one duct system is
necessary. In a randomized controlled prospec-
tive trial, De Palma et al.8 evaluated 157
patients with malignant hilar biliary obstruc-
tion due to cholangiocarcinoma, gallbladder
cancer or periportal metastatic lymphadenopa-
thy. In patients with unilateral stenting, there
was a higher success rate for stent insertion
(89% vs 77%) and drainage (81% vs 73%) and,
therefore, a lower early complication rate (19%
vs 27%) when compared to bilateral stenting of
both hepatic lobes. Early complications includ-
ed cholangitis and stent occlusion. No differ-
ences were found in survival or procedure-
related mortality.
Both plastic (polyethylene) and metal biliary
stents are available for use in cholangiocarci-
nomas. Numerous studies have compared
costs, complications and survival with both
types of stents.9-11 There are no differences in
survival with the use of either stents. Plastic
stents tend to occlude earlier and more fre-
quently with 30% occlusion rates after three
months and 70% after six months.11 It is,
therefore, recommended to change plastic
stents every three months in order to prevent
occlusion and cholangitis.
Metal stents have a longer patency of
approximately 12 months since they have larg-
er diameters than plastic stents (10 mm vs 3.8
mm).7 However, as outlined above, once placed
they can be difficult to manipulate or remove.
Additionally, the initial cost of a metal biliary
stent is higher, though with plastic stents
there are subsequent costs due to the need for
repeat procedures for stent replacement and
increased hospitalization for complications.
Overall, there is no significant difference in
the cost between metal and plastic stents,
though metal stents may be associated with
reduced hospital stay overall.
Tumor overgrowth through the mesh of
metal stents may lead to further problems with
biliary obstruction and sepsis. This may be
overcome by inserting plastic stents through
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the lumen of the metal stent, which appears to
be more cost-effective, or placement of a fur-
ther mesh metal stent where technically possi-
ble.11-14
The decision as to whether to use a plastic
or metal stent will frequently depend on the
patients’ overall health, expected length of sur-
vival, quality of life and local expertise. Often,
a plastic stent is placed initially while further
diagnostic workup is underway. Once the diag-
nosis has been made, and the patient has con-
firmed unresectable disease and a life
expectancy of more than six months, then the
plastic stent can be replaced with a metal
stent. Placement of a metal stent eliminates
the need for repeat procedures and their asso-
ciated risks.
The controversy over whether and how to
perform pre-operative biliary drainage in
patients with hilar cholangiocarcinoma contin-
ues. The British Society of Gastroenterology
guidelines for the diagnosis and treatment of
cholangiocarcinoma7 recommend that stents
should ideally not be inserted before assessing
resectability. A biliary stent may make it diffi-
cult to assess the proximal extent of the tumor
intraoperatively and may increase the risk of
infections postoperatively. However, elevated
bilirubin levels and liver dysfunction are fac-
tors that adversely affect postoperative morbid-
ity. Indications for biliary stent placement pre-
operatively include acute suppurative cholan-
gitis or prevention of cholangitis after a diag-
nostic ERCP is performed or if surgery is to be
delayed for an extended period of time. Pre-
operative drainage may also be beneficial in
certain patients who are severely malnour-
ished or as a technical aid in patients requir-
ing a difficult hilar dissection for proximal bil-
iary diseases.15-16
Pre-operative intrahepatic segmental
cholangitis is a major prognostic factor in the
outcome of major hepatectomy for biliary can-
cer.17 In addition, in patients undergoing liver
resection for hilar cholangiocarcinoma, future
liver remnant volume of less than 30% of total
liver volume is associated with increased risk
for hepatic insufficiency and death. Pre-opera-
tive biliary drainage of the future liver rem-
nant appears to improve outcome if the pre-
dicted volume is less than 30%. However, in
patients with future liver remnant volume of
30% or more, pre-operative biliary drainage
does not appear to improve perioperative out-
come.18
Accordingly, no randomized controlled trials
(RCTs) have been performed to clarify the
safety of major hepatectomy for cholestatic
patients with hilar cholangiocarcinoma. The
danger of obstructive jaundice increasing the
risk of infection have only been revealed in
experimental studies.19-21 Therefore, many
eastern hepatobiliary surgeons believe that
biliary drainage is mandatory if major hepate-
ctomy for patients with hilar cholangiocarcino-
ma is to be safe.22-25 Experimental studies have
revealed that pre-operative internal biliary
drainage is superior to external drainage in
liver regeneration and function after hepatec-
tomy in obstructive jaundice.26-27
No definite criteria or guidelines outlining
indications for pre-operative biliary drainage
are currently available. In patients with hilar
cholangiocarcinoma, pre-operative biliary
drainage may be performed by either percuta-
neous transhepatic biliary drainage or endo-
scopic biliary drainage. No consensus, howev-
er, has been reached regarding which method
is more appropriate. No reported study has
compared the effectiveness of percutaneous
transhepatic biliary drainage, endoscopic bil-
iary stenting, and endoscopic nasobiliary
drainage in patients with cholangiocarcino-
ma.28
Arguments against pre-operative biliary
drainage before pancreatoduodenectomy have
recently been gaining momentum.29 Three
RCTs have revealed that pre-operative percuta-
neous transhepatic biliary drainage does not
improve perioperative results.30-32 However,
these studies included a considerable number
of patients undergoing palliative surgery and a
small number undergoing major surgery. In
another RCT, pre-operative endoscopic biliary
drainage for malignant obstructive jaundice
was shown to have no demonstrable benefit.33
In a randomized trial comparing uncovered
and partially covered self-expandable metal
stents in the palliation of distal malignant bil-
iary obstruction, there was no significant dif-
ference in time to recurrent biliary obstruction
or patient survival between the partially cov-
ered and uncovered SEMS groups. Partially
covered SEMSs were associated with more
serious adverse events, particularly
migration.34 Similarly, there were no signifi-
cant differences in stent patency time, patient
survival time or complication rates between
covered and uncovered nitinol metal stents in
the palliative treatment of malignant distal bil-
iary obstruction. However, covered stents
migrated significantly more often compared
with uncovered stents, and tumor ingrowth
was more frequent in uncovered stents.35,36
RCTs comparing covered to uncovered stents
in patients with unresectable distal biliary
malignancies showed that the patency of cov-
ered stents was significantly higher than that
of uncovered stents.37 However, many studies
report an increased risk of cholecystitis (5%)
with the covered stents due to cystic duct
occlusion.37,38
One of the problems in endoscopic place-
ment of multiple plastic biliary stents is proxi-
mal dislocation of the first stent at the time of
subsequent stent insertions. A proximally dis-
located stent above the papilla may be very dif-
ficult to remove. Endoscopists from Tokyo,
Japan have reported a technique called the
anchor-wire technique, useful for preventing
proximal dislocation of proximal biliary stents
in endoscopic placement of multiple stents.39
To prevent proximal dislocation of the first
stent into the bile duct, a stiff guidewire is
inserted from the distal end of the first stent
through the distal side hole, leading it towards
the third portion of the duodenum and making
it work as an anchor-wire. Upon inserting the
second biliary stent, the anchor-wire success-
fully prevents proximal dislocation of the first
stent inclined to migrate into the bile duct, by
pulling it down.
Antibiotic prophylaxis should be given rou-
tinely in patients with hilar cholangiocarcino-
ma in whom it can be anticipated that com-
plete biliary drainage will be difficult or impos-
sible to achieve during one procedure. Patients
presenting with bacterial cholangitis should
already be established on antibiotics at the
time of ERCP. The preferred antibiotic is fre-
quently ciprofloxacin (750 mg orally 60-90 min
before the procedure) or gentamicin (1.5
mg/kg intravenously over 2-3 min).40
Review
Table 1. Indications for stent insertion during endoscopic retrograde cholangiopancre-
atography.
Cholangiocarcinoma with biliary obstruction
Pancreatic carcinoma with biliary obstruction 
Ampullary carcinoma undergoing endoscopic resection
Benign biliary strictures
Primary sclerosing cholangitis
Sphincter of Oddi dysfunction
Large or multiple common bile duct stones not retrieved during ERCP
Chronic pancreatitis with / without pancreatic duct stones
Pancreatic strictures
Pancreatic duct leaks
Post-ERCP pancreatitis prophylaxis
Post-cholecystectomy biliary injuries
ERCP, endoscopic retrograde cholangiopancreatography.
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Pancreatic carcinoma
Common bile duct stents are frequently
used to endoscopically decompress the biliary
system in malignant pancreatic head cancer. It
was unclear whether plastic or metal stents
were more suitable for pre-operative biliary
decompression in pancreatic cancer, but new
data now show SEMS to be superior to plastic
stents.41,42 In patients undergoing neoadjuvant
chemoradiotherapy, plastic biliary stents do
not maintain patency long enough to complete
the treatment. Placement of SEMS appears to
give safe and efficacious palliation for biliary
and duodenal obstruction due to unresectable
pancreatic head carcinoma. The majority of
patients do not require further intervention
and those who do can usually be managed
without surgery.43-44
The presence of distant metastases was
identified as the only independent prognostic
factor for survival after initial biliary drainage.
An SEMS should be systematically chosen for
patients without distant metastases (median
survival 6.6 months), whereas polyethylene
plastic stents should be preferred in patients
with distant metastases (median survival 3.1
months).45 There appears to be no difference
in efficacy, duration of stent patency, occlusion
rates and complications between the nitinol
and the stainless steel uncovered metal
stents.46 With the use of chemotherapy,
patients who are palliated with metal stents
are now surviving longer, and these long-term
survivors with metal stents have been shown
to have greater odds of developing cholangitis
(11.5% for those surviving one year or under
compared to 46.5% surviving more than one
year).47 Retrospective analysis has also shown
a higher risk of post-ERCP pancreatitis for
malignant biliary obstruction with metal stents
when compared to plastic stents with no sig-
nificant difference between covered and
uncovered stents.48 Duodenal invasion is a risk
factor for early self-expandable metal stent
dysfunction in patients with pancreatic can-
cer.49
Pre-operative biliary drainage before sur-
gery for cancer of the pancreatic head does not
appear to affect survival rate.50 However,
cholangitis remains a formal indication for
early, urgent pre-operative biliary decompres-
sion for patients with pancreatic cancer.51
The application of endobiliary SEMS is con-
sidered the palliative treatment of choice in
patients with biliary obstruction in the setting
of inoperable malignancies. In the presence of
SEMS, however, radical surgery is the only cur-
ative option when the resectability status is
revised in case of malignancies. Revising the
initial palliative approach and operating in the
setting of biliary metallic stents is extremely
demanding and carries significant mortality
and morbidity. Radical resection is the only
option for offering cure in such complex cases,
and this should only be attempted in advanced
hepatopancreaticobiliary centers with active
involvement in liver transplantation.52
Other authors53 recommend that the place-
ment of the newly available CSEMS can be
used to effectively and safely treat biliary
obstructions from pancreatic carcinoma and as
an initial intervention to relieve malignant bil-
iary obstruction, even in patients whose surgi-
cal resectability status is uncertain. Stenting
of biliary obstruction due to pancreatic adeno-
carcinoma before endoscopic ultrasound does
not influence the rate of tissue diagnosis if
performed more than one day before EUS-FNA.
Lack of immediate endoscopic ultrasound
access should not preclude stent placement in
appropriate patients with malignant biliary
obstruction who will undergo EUS-FNA.54Ampullary adenocarcinoma
Ampullary tumors account for approximately
5% of all gastrointestinal neoplasms affecting
0.04-0.64% of the general population in autop-
sy series.55-57 The most commonly affected
patients are those with familial adenomatous
polyposis with a 50-100% lifetime incidence of
peri-ampullary adenomas.58-60 The associated
morbidity and mortality of surgical resection
for ampullary adenomas has led clinicians to
seek less invasive techniques with endoscopic
ampullectomy being first described in the
1980s.61 The first prospective RCT of the use of
prophylactic pancreatic duct stenting for endo-
scopic ampullectomy published in 2005 was
prematurely terminated because of an elevated
incidence of pancreatitis in the group without
pancreatic stenting (33% vs 0%) and suggest-
ed that pancreatic stent placement confers a
protective effect.62
Endoscopic ampullectomy guidelines have
not been established. A literature review by
Han et al. reveals diverse endoscopic practices
regarding the use of biliary/pancreatic sphinc-
terotomy, use and timing of pancreatic stent-
ing, thermal ablation therapy and follow-up in
ampullectomy.63 Though pancreatic duct stent-
ing after endoscopic papillectomy of ampullary
neoplasms is expected to contribute to the pre-
vention of post-papillectomy pancreatitis,
there is no consensus regarding the mode of
resection, current or need for addition of bil-
iary/pancreatic sphincterotomy and biliary
stenting.64 Also, in a pilot study on 11 patients
with ampullary neoplasm, pre-resection stent-
ing with a polytetrafluoroethylene-insulated
stent was shown to be feasible in the preven-
tion of post-papillectomy pancreatitis.65
Prophylactic stenting of both the pancreatic
and the biliary systems may further reduce
post-endoscopic ampullectomy complica-
tions.66
Benign biliary strictures
Endoscopic treatment is the mainstay of
therapy for benign billiary strictures and sur-
gery is reserved for selected patients in whom
endoscopic treatment fails or is not feasible.
The endoscopic approach depends on stricture
etiology and location, and generally involves
the placement of one or multiple plastic stents,
dilation of the stricture or a combination of
these approaches.67 In benign strictures, endo-
scopic dilatation with short-term stenting
seems to be effective and safe, and does not
increase the risks of malignant transformation
or complications after liver transplantation.
Surgical bile duct resection and/or bilioenteric
bypass are indicated only in patients with pre-
served liver function.68
Benign biliary strictures respond to place-
ment of multiple large-bore plastic stents,
although they require multiple procedures to
exchange stents to prevent and/or treat stent
occlusion. CSEMS, intended for palliation of
malignant biliary obstruction, have been used
to treat benign biliary diseases. Advantages
include small pre-deployment and large post-
expansion diameters. Lack of imbedding of the
metal into the bile duct wall facilitates
removal. For strictures, one CSEMS is inserted
without the need for dilation and remains in
place for up to six months. Successful removal
has been reported in all cases. Long-term stric-
ture resolution is achieved in up to 92%.
Adverse events include migration and new
stricture formation. For treatment of complex
bile leaks, the covering and large diameter
allow successful closure in nearly all cases.
Other uses of CSEMS include treatment of
postsphincterotomy bleeding and closure of
perforations.69
Multiple plastic biliary stents for benign
non-hilar strictures were associated with a low
rate of premature symptomatic stent occlusion
at more than six months and a longer occlu-
sion-free survival, thus suggesting that stents
in benign strictures last longer and require
less frequent replacement.70Primary sclerosing cholangitis
Most patients with primary sclerosing
cholangitis (PSC) develop fibrotic stenoses of
the larger bile ducts. In patients with total or
subtotal strictures of the large bile ducts, these
so-called dominant stenoses may be treated by
endoscopic balloon dilatation and/or stent
placement, though in the large majority of
cases a stent placement is not necessary.71,72
In fact, in a study by Gotthardt et al. on 171 PSC
patients, 97 patients developed dominant stric-
tures which were managed with 500 balloon
dilatations and 5 stents.73 In a study by Kaya et
al. on 71 PSC patients, 34 patients were treat-
ed with endoscopic balloon dilation alone, and
37 patients were treated with balloon dilation
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plus stent placement. There was no additional
obvious benefit from stenting after balloon
dilation in the treatment of dominant stric-
tures in PSC patients. Stenting was also asso-
ciated with more complications.74 Stenting
may, however, still be necessary in those stric-
tures which are resistant to dilatation, or
where frequent repeat dilatation is necessary.Sphincter of Oddi dysfunction
Pancreatic duct stenting gives significant
protection against post-ERCP pancreatitis in
patients with pancreatic sphincter hyperten-
sion undergoing biliary sphincterotomy.
Stenting of the pancreatic duct should be
strongly considered after biliary sphincteroto-
my for sphincter of Oddi dysfunction (SOD);
pancreatic sphincter of Oddi manometry iden-
tifies which high-risk patients may benefit
from pancreatic stenting.75 However, patients
with suspected SOD who are found to have
normal manometry results are also at high risk
for post-ERCP pancreatitis. In a study by Saad
et al.76 of 403 patients with suspected SOD but
normal manometry, pancreatitis rates were
2.4% in the group undergoing prophylactic
pancreatic duct stenting and 9.0% in the group
who were not stented. The authors, therefore,
concluded that temporary pancreatic duct stent
placement reduces pancreatitis rates in
patients with suspected SOD but normal
manometry and an intact papilla. Their routine
use is recommended when evaluating this dif-
ficult, high-risk patient population.Large or multiple common bile ductstones
Difficult cases of bile duct stones are fre-
quently treated successfully with lithotripsy. A
stent should be applied when the common bile
duct cannot be cleared completely.77 Little
information is available on the outcomes of
endoscopic sphincterotomy plus biliary stent
placement without stone extraction as primary
therapy at ERCP in the treatment of large or
multiple common bile duct stones. Hong et al.
retrospectively analyzed 52 patients with large
(>20 mm) or multiple (3 or more) stones.78
The patients underwent endoscopic sphinc-
terotomy and placement of plastic stents in the
bile duct without stone extraction at the initial
ERCP. Three or more months later, a second
ERCP was carried out and stone removal was
attempted. Differences in stone size and the
largest CBD diameter before and after stenting
were compared. Stone clearance and complica-
tions were also evaluated. After a median of
124 days of biliary plastic stent placement, the
mean maximal stone diameter decreased from
16.6 mm to 10.0 mm (P<0.01). The mean CBD
diameter also decreased from 15.3 mm to 11.5
mm (P<0.01). The total stone clearance at sec-
ond ERCP was 94.2%, only 5.7% of which need-
ed mechanical lithotripsy. Biliary plastic stents
plus endoscopic sphincterotomy without stone
extraction as primary therapy at initial ERCP
appears to be a safe and effective method in
the management of large or multiple CBD
stones. These findings were further replicated
in 2 other studies by Fan et al.79 and Horiuchi
et al.80
Itoi et al.81 have described a new device for
the removal of large bile duct stones. This is a
combination of a large-diameter dilating bal-
loon and sphincterotome. In a study on 18
patients, sphincterotomy was performed using
this device, the catheter was then advanced
into the bile duct and balloon dilation was per-
formed by gradual inflation with diluted con-
trast medium under endoscopic and fluoro-
scopic guidance until it reached a diameter
which allowed the stone to be removed.
Technical success of large-diameter balloon
dilatation after sphincterotomy was achieved
in all cases with bile duct clearance performed
in all but one case in the first session and bile
duct clearance achieved in all cases on repeat
endoscopy. No major complications were
described.81Chronic pancreatitis
The preferred therapeutic option in the
management of chronic pancreatitis caused by
stones is extracorporeal shock wave lithotrip-
sy.An alternative involves the use of stents
placed in the pancreatic duct endoscopically.
Reports indicate that 30-76% of patients
receiving such stents have symptomatic
improvement over a period of 14-36 months of
observation.82 Although these results seem
encouraging, most of the data reported so far
have been from relatively short-term, non-ran-
domized studies. The issue is further compli-
cated by the fact that pancreatic duct stents
may not be entirely harmless; they may cause
further pancreatic duct changes and potentiate
chronic pancreatitis.83 Endoprosthesis occlu-
sion and migration also seem to be relatively
common.
Endoscopic stent drainage of both the pan-
creatic and the biliary duct for chronic pancre-
atitis with distal biliary benign strictures is an
effective and minimally invasive therapeutic
method. In a study by Zheng et al.,84 22
patients diagnosed with chronic pancreatitis
with distal benign biliary stricture underwent
endoscopic treatment with ERCP, endoscopic
sphincterotomy, endoscopic retrograde biliary
drainage (ERBD) and endoscopic retrograde
pancreatic drainage (ERPD) with stents. Sixty-
eight ERCPs were successfully performed in 21
patients with 47 pancreatic duct stents and 39
biliary duct stents inserted. The rate of compli-
cations was 13.2% (9/68). The abdominal pain
score after endoscopic treatment was signifi-
cantly reduced. The levels of bilirubin and ala-
nine transaminase in all 21 patients were also
improved compared to those before endoscopic
treatment.Pancreatic duct strictures
Benign strictures of the main pancreatic
duct are generally due to inflammation or
fibrosis around the main pancreatic duct.
Because ductal obstruction may lead to pain or
acute pancreatitis superimposed on chronic
pancreatitis, endoscopic therapy with balloon
dilation or pancreatic duct stents for the treat-
ment of dominant pancreatic duct strictures
has been evaluated. Stricture dilation may be
required to facilitate stent placement or stone
removal.82 Data regarding the role of endo-
scopic therapy in treating main pancreatic
duct strictures are inconsistent. Some, but not
all, authors have reported high success rates
(75-94%) in treating pain by stenting of pan-
creatic duct strictures.85-87
In addition, although some authors have
correlated clinical improvement to a decrease
in the diameter of the main pancreatic duct
upstream, others have not. Pancreatic stents
are prone to occlusion and patients undergo-
ing endoscopic therapy for pancreatic duct
strictures may require frequent stent
exchanges. Symptomatic improvement may
persist after pancreatic stent removal despite
persistence of the stricture. Confounding fac-
tors in the literature on pancreatic stent thera-
py are other therapies performed at the time of
stent placement (e.g. pancreatic sphincteroto-
my, pancreatic stone removal) and the tenden-
cy of the chronic pancreatitis pain to come and
go and decrease with time as pancreas func-
tion deteriorates. The optimum duration of
stent placement, stent number and diameter
and degree of balloon dilation are not known.
Complications related to endoscopic therapy of
pancreatic duct strictures include pain, pan-
creatitis, stent occlusion, proximal or distal
stent migration, duodenal erosions, pancreatic
infection, ductal perforation, and bleeding
from pancreatic sphincterotomy.
The role of placing multiple stents in the
pancreatic duct has been assessed by
Costamagna et al.87 Nineteen patients with
severe chronic pancreatitis and with a single
pancreatic stent through a refractory dominant
stricture in the pancreatic head underwent
removal of this stent followed by balloon dila-
tion of the stricture and insertion of the maxi-
mum number of stents allowed by the tight-
ness of the stricture and the caliber of the pan-
creatic duct diameter. Stents were removed
after 6-12 months. A median of 3 stents were
placed through the major or minor papilla;
stent diameter ranged from 8.5 to 11.5 Fr and
length from 4 to 7 cm. During a mean follow up
of 38 months after stent removal, 84% of
patients were asymptomatic and 11% had
symptomatic stricture recurrence. No major
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complications were recorded. This study
showed that endoscopic multiple stenting of a
dominant pancreatic duct stricture is feasible
and safe.Pancreatic duct leaks
Pancreatic duct disruptions or leaks can
occur as a result of severe acute pancreatitis or
chronic pancreatitis. Pancreatic duct leaks can
often be treated with endoscopic placement of
transpapillary stents in a manner similar to the
use of biliary stents for closing bile duct
leaks.88 Endoscopic therapy is successful in
closing the leaks in approximately 60% of
patients. Factors associated with a better out-
come in duct disruption include a partial dis-
ruption, successfully bridging the disruption
with a stent, and longer duration of stent
placement (approximately 6 weeks). Major
pancreatic disruption secondary to pancreatic
trauma can also be managed by pancreatic
duct stenting.89Post-endoscopic retrogradecholangiopancrea pancreatitis pro-phylaxis
Pancreatitis is the most common and poten-
tially serious complication following ERCP.
Post-ERCP pancreatitis (PEP) is caused most-
ly by postprocedural papillary edema and reten-
tion of pancreatic juice. The European Society
of Gastrointestinal Endoscopy guidelines on
the prophylaxis of post-ERCP pancreatitis90
recommend that prophylactic pancreatic stent
placement helps prevent post-ERCP pancreati-
tis in patients who are at high risk. Short 5-Fr
diameter plastic pancreatic stents are current-
ly recommended. Passage of the stent from the
pancreatic duct should be evaluated within 5-
10 days of placement and retained stents
should be promptly removed endoscopically.
In a randomized controlled trial on 426
patients at 37 endoscopic units, Sofuni et al.91
showed that placement of a pancreatic duct
stent reduces the incidence of PEP and that
several risk factors are associated with PEP.
Patients were assigned randomly to groups
that received (S group, n=213) or did not (nS
group, n=213) receive stents. The stent used
was temporary, 5F in diameter, 3 cm long, and
straight with an unflanged inner end. The fre-
quencies of PEP in the S and nS groups were
7.9 and 15.2%, respectively; the lower inci-
dence of PEP in the S group was statistically
significant based on the full analysis set
(P=0.021). There were significant differences
in PEP incidence between groups in multivari-
ate analysis for the following risk factors: pan-
creatography first, non-placement of a pancre-
atic duct stent after ERCP, procedure time of 30
min or more, sampling of pancreatic tissue by
any method, intraductal ultrasonography, and
difficulty of cannulation (≥15 min). Patients
with more than 3 risk factors had a significant-
ly greater incidence of pancreatitis.
A meta-analysis of eight randomized con-
trolled trials92 (656 subjects) showed that pro-
phylactic pancreatic stents decreased the odds
of post-ERCP pancreatitis (odds ratio 0.22; 95%
CI 0.12-0.38; P<0.01) with 8 needed in order to
treat. Stents also decreased the level of hyper-
amylasaemia. The size of the ideal pancreatic
stent to prevent post-ERCP pancreatitis has yet
to be determined. Pahk et al.93 reviewed the
outcomes of 346 prophylactic pancreatic stents
in 308 patients and showed that prophylactic
stents significantly reduced the risk of post-
ERCP pancreatitis and nearly eliminated
severe pancreatitis. There was no significant
difference between the 4 Fr and 5 Fr stents in
the reduction of post-ERCP pancreatitis but
spontaneous migration was more frequent
with the 4-Fr stent. Zolotarevsky et al.94 have,
however, shown that placement of 5Fr pancre-
atic stents is easier, faster and requires fewer
wires than the 3Fr stent.
Removal of retained prophylactic pancreatic
stents may cause mild or moderate acute pan-
creatitis. In a study by Moffatt et al.,95 acute
pancreatitis occurred after prophylactic pan-
creatic stent removal in 7 of 230 (3.0%) cases
of retained stents. This risk of acute pancreati-
tis may diminish the overall efficacy of prophy-
lactic stents use by delaying the occurrence of
post-ERCP pancreatitis rather than eliminat-
ing it. This implies that prophylacyic pancreat-
ic stents should be used only in patients at
high risk for post-ERCP pancreatitis. Among
the complications of pancreatic stenting, prox-
imal (upstream) migration of pancreatic
stents occurs with a reported incidence of 5.2%
and may induce morphological changes in the
pancreatic duct and pancreatitis if left without
retrieval.96-101 Similar to extraction of migrated
biliary stents, more than 80% of proximally
migrated pancreatic stents can be retrieved
endoscopically by indirect traction with stone
extraction balloon or direct traction with for-
eign body grasp forceps, snares or basket.102-106
In difficult cases, several retrieval techniques
have been successfully applied and introduced
in case reports, including the wire-guided
snare lasso technique,107 using a Soehendra
stent retriever, SpyGlass assisted stent
retrieval,108 and interventional cardiology
accessories.109
Gong et al.110 have described an algorithm
that has allowed them to retrieve all of 15 pan-
creatic stents (5Fr n=6; 7Fr n=9) that had
migrated proximally. The stent retrieval was
performed by an experienced endoscopist. The
existing strictures in the proximal pancreatic
duct were dilated with dilation balloon or
bougie before stent retrieval. Endoscopic
sphincterotomy or dilation was performed on
the intact minor papilla if retrieval of the prox-
imally migrated pancreatic stents (PMPS)
from the dorsal pancreatic duct was necessary.
All of the PMPSs were retrieved initially with
balloon extraction by inflating an over-the-wire
stone extraction balloon alongside or above the
migrated stent and dragging the stent distally.
If balloon extraction failed after five attempts,
another accessory was used. In patients with-
out pancreatic duct dilation, a rat-tooth forceps
was introduced into the pancreatic duct by
grasping the guide wire to the distal end or the
shaft of the stent. Direct grasping of the stent
was then conducted under fluoroscopy. If this
approach failed after five attempts, a rescue
approach was attempted. In patients with pan-
creatic duct dilation, retrieval with a rat-tooth
forceps was also tried first. If it failed after five
attempts, a wire-guided basket was used to
grasp the stent and a rescue approach was con-
sidered after five failed attempts.
Recently, wire-guided selective cannulation
of the bile duct has been proposed as a tech-
nique with a high rate of success and less risk
of post-ERCP pancreatitis. Nambu et al.111
compared the post-ERCP pancreatitis rates
using the wire-guided cannulation method (86
cases) with the standard cannulation method
(86 cases). The standard method had a post-
ERCP pancreatitis rate of 6% while only 2.3%
of the wire-guided method had post-ERCP pan-
creatitis. In addition, all cases of pancreatitis
in the wire-guided cannulation group were
mild, with a comparable success rate of cannu-
lation between both groups.111Post-cholecystectomy biliaryinjuries
Bile leak from tears in the biliary system fol-
lowing cholecystectomy is a complication
which can be managed by stent insertion dur-
ing ERCP.112,113 Endoscopic stenting helps to
avoid surgery in more than 80% of patients
bearing postcholecystectomy common bile duct
strictures. However, in a long-term follow up
after biliary stent placement for postcholecys-
tectomy biliary strictures, Tuvignon et al.114
showed that a persistent anomaly on cholan-
giography at the time of stent removal is a
strong predictor of recurrence and may lead to
surgery being considered. Biliary stenting
seems to be a more effective method than
endoscopic sphincterotomy in the manage-
ment of postcholecystectomy bile leakage and
without CBD dilatation.115Biliary strictures after liver trans-plantation
Biliary strictures are one of the most com-
mon complications following liver transplanta-
tion, representing an important cause of mor-
bidity and mortality in transplant recipients.
The reported incidence of biliary stricture is 5-
15% following deceased donor liver transplan-
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tations (DDLT) and 28-32% following living
donor liver transplantations (LDLT).116 Bile
duct strictures following liver transplantation
are classified as anastomotic (AS) or non-
anastomotic strictures (NAS). NAS are charac-
terized by a far less favorable response to
endoscopic management, higher recurrence
rates, graft loss and the need for retransplanta-
tion. Current endoscopic strategies to correct
biliary strictures following liver transplanta-
tion include repeated balloon dilatations and
the placement of multiple side-by-side plastic
stents. Endoscopic balloon dilatation with
stent placement is successful in the majority of
AS patients. In patients for whom gaining bil-
iary access is technically difficult, a combined
endoscopic and percutaneous/surgical
approach proves quite useful. 
Management of patients with NAS is diffi-
cult since the accumulation of biliary sludge
and casts makes therapy particularly difficult
because of rapid stent occlusion. Treatment of
NAS did not result in significant long-term
improvement of liver chemistries. The poor
response of non-anastomotic stenoses to treat-
ment does not seem to vary with etiology.117
Most importantly, NAS resulted in significantly
increased graft loss.
NAS in LDLT are more resistant to endo-
scopic treatment with average success rate of
25-33%, which is far below the 60% success
rate seen with NAS in DDLT.118,119 Endoscopic
therapy of non-anastomotic strictures typically
consists of extraction of the biliary sludge and
casts and balloon dilation of all accessible
strictures followed by placement of plastic
stents with 3-monthly replacement.117
However, balloon dilation of all strictures is not
feasible and rapid stent clogging frequently
occurred when managing NAS. Therefore,
patients with NAS may require early retrans-
plantation and endoscopic therapy appears to
play a more prominent role as a bridge to liver
retransplantation.119
In anastomotic strictures, the conventional
method of endoscopic treatment consists of
identification of the opening of the stricture
followed by cannulation by the guidewire, bal-
loon dilatation of the stricture, and subsequent
placement of plastic stents. Balloon dilation
alone without stent placement is only success-
ful in approximately 40% of cases.120 However,
balloon dilation with additional stent place-
ment appears to be more successful with a
durable outcome in 75% of patients with anas-
tomotic strictures. The stents are generally
replaced by larger stents every three months to
prevent the complication of clogging, cholangi-
tis, or stone formation.121 Dual or multiple
stents provide greater dilatation and have,
therefore, shown better results than single
stents.119 Placement of not one, but multiple
side-by-side plastic stents, further increases
successful outcomes in 80-90% of
patients.122,123
In some patients, a transient narrowing at a
duct to duct connection appear within the first
30 to 60 days after transplantation, due to post-
operative edema and inflammation. This type
of stricture responds well to balloon dilatation
and temporary stent placement.124 Most
patients with anastomotic strictures require
repeat ERCP sessions every three months with
balloon dilation of 6-10 mm and multiple stents
of 7-10 Fr repeated for 12-24 months.124,125 An
increasing number of stents can be used at
each session to achieve a maximum diameter.
The treatment is usually completed in one year
with an average of 3-4 stent exchange ses-
sions. The overall long-term success rate of
endoscopic treatment for AS associated with
DDLT is in the range of 70-100%.126-128
However, endoscopic treatment success
rates in AS after LDLT appear significantly
lower than AS for DDLT at 37-71%.129,130 When
AS are treated appropriately, the long-term
results in terms of patient and graft survival
are the same as those for matched controls
without AS.131 A protocol of accelerated dila-
tion every two weeks, and a shortened stenting
period of an average of 3.6 months, showed
some encouraging results with a high 87%
success rate.123 In patients with duct to duct
anastomosis, endoscopic management is,
therefore, first line, and it appears that while
repeat endoscopic treatment is needed, short-
er intervals between treatments may ultimate-
ly reduce the time needed for successful long-
term outcomes. Despite limited data, there is
some experience in temporary placement of
CSEMS to reduce the need for repeated stent
exchanges but long-term results are not yet
available.
Conclusions
ERCP stents are one of the most important
tools in the endoscopic management of hepa-
tobiliary and pancreatic diseases. Plastic and
metal stents have specific indications. The
covered self-expandable metal stents have
been shown to be safe to use in a number of
conditions, particularly those which require
prolonged (>3 months) stenting.
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